49,062 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Annexon, Inc. (NASDAQ:ANNX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,062 shares of the company’s stock, valued at approximately $252,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANNX. Rhumbline Advisers boosted its holdings in shares of Annexon by 4.3% in the 4th quarter. Rhumbline Advisers now owns 141,852 shares of the company’s stock valued at $728,000 after purchasing an additional 5,854 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in Annexon by 143.4% in the fourth quarter. New York State Common Retirement Fund now owns 34,479 shares of the company’s stock valued at $177,000 after acquiring an additional 20,311 shares during the last quarter. Bank of New York Mellon Corp grew its position in Annexon by 2.8% during the fourth quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company’s stock valued at $1,183,000 after acquiring an additional 6,226 shares during the period. Mutual of America Capital Management LLC grew its position in Annexon by 56.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock valued at $5,282,000 after acquiring an additional 370,426 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Annexon by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 743,795 shares of the company’s stock worth $3,816,000 after acquiring an additional 11,579 shares during the last quarter.

Wall Street Analyst Weigh In

ANNX has been the topic of several research analyst reports. HC Wainwright reduced their price objective on Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Needham & Company LLC dropped their target price on shares of Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th.

Annexon Trading Up 7.5%

NASDAQ:ANNX opened at $2.71 on Friday. The firm’s fifty day simple moving average is $1.91 and its 200 day simple moving average is $3.13. Annexon, Inc. has a twelve month low of $1.29 and a twelve month high of $7.85. The firm has a market capitalization of $297.32 million, a price-to-earnings ratio of -2.58 and a beta of 1.26.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.